Intel shares soar on surprise profit, but analysts say ‘fight far from over’

Intel shares jump after breaking six-quarter losing streak as cost cuts and strategic investments lift earnings and signal a ...

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available ...